Ozempic maker Novo Nordisk posts strong results but competition weighs / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File
-
Stock market optimism returns after tech selloff but Wall Street wobbles
-
Clarke warns Scotland fans over sky-high World Cup prices
-
In Israel, Sydney attack casts shadow over Hanukkah
-
Son arrested after Rob Reiner and wife found dead: US media
-
Athletes to stay in pop-up cabins in the woods at Winter Olympics
-
England seek their own Bradman in bid for historic Ashes comeback
-
Decades after Bosman, football's transfer war rages on
-
Ukraine hails 'real progress' in Zelensky's talks with US envoys
-
Nobel winner Machado suffered vertebra fracture leaving Venezuela
-
Stock market optimism returns after tech sell-off
-
Iran Nobel winner unwell after 'violent' arrest: supporters
-
Police suspect murder in deaths of Hollywood giant Rob Reiner and wife
-
'Angry' Louvre workers' strike shuts out thousands of tourists
-
EU faces key summit on using Russian assets for Ukraine
-
Maresca committed to Chelsea despite outburst
-
Trapped, starving and afraid in besieged Sudan city
-
Showdown looms as EU-Mercosur deal nears finish line
-
Messi mania peaks in India's pollution-hit capital
-
Wales captains Morgan and Lake sign for Gloucester
-
Serbian minister indicted over Kushner-linked hotel plan
-
Eurovision 2026 will feature 35 countries: organisers
-
Cambodia says Thailand bombs province home to Angkor temples
-
US-Ukrainian talks resume in Berlin with territorial stakes unresolved
-
Small firms join charge to boost Europe's weapon supplies
-
Driver behind Liverpool football parade 'horror' warned of long jail term
-
German shipyard, rescued by the state, gets mega deal
-
Flash flood kills dozens in Morocco town
-
'We are angry': Louvre Museum closed as workers strike
-
Australia to toughen gun laws as it mourns deadly Bondi attack
-
Stocks diverge ahead of central bank calls, US data
-
Wales captain Morgan to join Gloucester
-
UK pop star Cliff Richard reveals prostate cancer treatment
-
Mariah Carey to headline Winter Olympics opening ceremony
-
Indonesia to revoke 22 forestry permits after deadly floods
-
Louvre Museum closed as workers strike
-
Spain fines Airbnb 64 mn euros for posting banned properties
-
Japan's only two pandas to be sent back to China
-
Zelensky, US envoys to push on with Ukraine talks in Berlin
-
Australia to toughen gun laws after deadly Bondi shootings
-
Lyon poised to bounce back after surprise Brisbane omission
-
Australia defends record on antisemitism after Bondi Beach attack
-
US police probe deaths of director Rob Reiner, wife as 'apparent homicide'
-
'Terrified' Sydney man misidentified as Bondi shooter
-
Cambodia says Thai air strikes hit home province of heritage temples
-
EU-Mercosur trade deal faces bumpy ride to finish line
-
Inside the mind of Tolkien illustrator John Howe
-
Mbeumo faces double Cameroon challenge at AFCON
-
Tongue replaces Atkinson in only England change for third Ashes Test
-
England's Brook vows to rein it in after 'shocking' Ashes shots
-
Bondi Beach gunmen had possible Islamic State links, says ABC
NYSE - LSE
| RYCEF | 2.01% | 14.9 | $ | |
| RBGPF | -4.49% | 77.68 | $ | |
| CMSC | 0.02% | 23.305 | $ | |
| SCS | 0.12% | 16.14 | $ | |
| BCC | -1.23% | 75.58 | $ | |
| CMSD | 0.26% | 23.31 | $ | |
| GSK | 0.65% | 49.13 | $ | |
| NGG | 0.9% | 75.61 | $ | |
| RIO | -0.25% | 75.473 | $ | |
| BCE | 0.77% | 23.575 | $ | |
| AZN | 1.39% | 91.1 | $ | |
| JRI | 0.17% | 13.59 | $ | |
| RELX | 1.82% | 41.13 | $ | |
| VOD | 1.22% | 12.745 | $ | |
| BTI | 0.76% | 57.535 | $ | |
| BP | -0.38% | 35.125 | $ |
Ozempic maker Novo Nordisk posts strong results but competition weighs
Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition is weighing on sales of its diabetes and obesity treatments Ozempic and Wegovy in the United States.
The group reported a net profit of 26.5 billion kroner ($4.1 billion), a 32 percent increase from the same period last year, while sales increased by 18 percent to 76 billion kroner.
The drug maker lowered its annual earnings outlook last week, causing its share price to continue its nearly year-long slide.
The company had already cut its forecast in May and announced the departure of its chief executive Lars Fruergaard Jorgensen.
"In May we mostly thought the bottom was reached," Mikael Bak, director of the Danish shareholders' association, told AFP.
Bak said "every is a bit surprised" that the situation has deteriorated.
"So now we don't want to see more disappointments, there are reasons to believe the business is healthy, the institution and the products good," he said.
Novo Nordisk announced last week that it was promoting Maziar Mike Doustdar, its vice president for international operations, to succeed Jorgensen.
The popularity of Novo Nordisk's weight-loss treatments had once made it a darling of investors, boosting its share price and at one point making it Europe's most valuable company.
But it now faces growing competition from rival treatments made by US group Eli Lilly in United States.
A rule by the US Food and Drug Administration allowing pharmacies to create so-called "compound" copycat versions of the drug, after high demand led to shortages, has also dented Novo Nordisk's earnings.
R.Lee--AT